Citi analyst Geoff Meacham lowered the firm’s price target on AbbVie (ABBV) to $235 from $240 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $261 from $255 at Morgan Stanley
- Ironwood jumps after AbbVie reports Linzess sales beat
- AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow
- Midday Fly By: Apple, Amazon upbeat reports lift Nasdaq
- AbbVie’s Strong Financial Performance and Growth Potential Justifies Buy Rating